trial · primary record
Engineered Immune Cells
Cancer
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | TERMINATED |
| Sponsor | Unknown |
| Enrolment | 100 |
| Primary completion | 2026-07-31 |
| Primary endpoint | percentage of adverse effects after EIE cell injection |
| Registry ID | NCT03535246 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-11-04T03:54:28.774Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT03535246
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Engineered Immune Cells · compound